Outlook Therapeutics (NASDAQ: OTLK) adds $100M ATM, reports $7.7M cash
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. entered into a new At The Market Offering Agreement with H.C. Wainwright, allowing the company to sell up to $100,000,000 of common stock from time to time under its effective Form S-3 shelf registration. H.C. Wainwright will act as sales agent and/or principal and earn a 3% commission on gross proceeds.
In connection with this new agreement, Outlook Therapeutics terminated its prior $100,000,000 at-the-market program with BTIG and will no longer sell shares under that facility. The company also reported preliminary, unaudited cash and cash equivalents of approximately $7.7 million as of March 31, 2026, excluding $4.5 million of net proceeds from an April 2026 registered direct equity offering.
Positive
- None.
Negative
- None.
Insights
Outlook Therapeutics sets a new $100M ATM while disclosing a modest cash balance.
Outlook Therapeutics put in place a new at-the-market equity program of up to $100,000,000 with H.C. Wainwright, replacing a prior ATM of the same size with BTIG. The company pays a 3% commission on gross proceeds from any share sales under this arrangement.
The filing also notes preliminary cash and cash equivalents of about $7.7 million as of March 31, 2026, excluding $4.5 million in net proceeds from an April 2026 registered direct offering. This combination of limited reported cash and substantial ATM capacity underscores the company’s reliance on external equity financing, though the scale and timing of any future issuances will depend on management’s decisions and market conditions.
8-K Event Classification
4 items: 1.01, 1.02, 2.02, 9.01
4 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
ATM program size: $100,000,000
Sales agent commission: 3% of gross proceeds
Preliminary cash balance: $7.7 million
+2 more
5 metrics
ATM program size
$100,000,000
Maximum aggregate offering price for new ATM with H.C. Wainwright
Sales agent commission
3% of gross proceeds
Commission payable to H.C. Wainwright on ATM share sales
Preliminary cash balance
$7.7 million
Cash and cash equivalents as of March 31, 2026, unaudited
Additional net proceeds
$4.5 million
Net proceeds from registered direct equity offering in April 2026
Prior ATM size
$100,000,000
Maximum aggregate offering price under terminated BTIG ATM program
Key Terms
At The Market Offering Agreement, shelf registration statement, Rule 415(a)(4), registered direct equity offering, +1 more
5 terms
At The Market Offering Agreement financial
"entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
shelf registration statement regulatory
"The offering has been registered under the Securities Act pursuant to the Company’s shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
Rule 415(a)(4) regulatory
"deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act"
Rule 415(a)(4) is a U.S. Securities and Exchange Commission rule that lets a company add more securities to an already effective shelf registration, so those additional shares or bonds can be sold later without filing a completely new registration. For investors it matters because it gives the issuer the flexibility to raise cash quickly—like having an open credit line—while creating the possibility of dilution or changes in supply that can affect share price.
registered direct equity offering financial
"does not include $4.5 million of net proceeds from a registered direct equity offering completed in April 2026"
A registered direct equity offering is a company’s sale of new shares that are pre-filed with regulators and sold directly to selected investors rather than through a broad public offering. Investors should care because it raises cash quickly but increases the total number of shares outstanding, which can dilute existing holders’ ownership and affect the stock price, much like adding more slices to the same-size pie.
forward-looking statements regulatory
"This on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What new financing arrangement did Outlook Therapeutics (OTLK) announce?
Outlook Therapeutics entered a new At The Market Offering Agreement with H.C. Wainwright, enabling sales of up to $100,000,000 in common stock. Shares may be sold over time on Nasdaq or in other permitted transactions under the existing Form S-3 shelf.
How much stock can Outlook Therapeutics sell under the new ATM program?
The company may sell up to $100,000,000 of common stock through H.C. Wainwright. Sales can occur from time to time at market or related prices, giving Outlook Therapeutics flexibility in how and when it raises additional equity capital.
What commission will H.C. Wainwright receive in the Outlook Therapeutics ATM?
H.C. Wainwright will receive a commission equal to 3% of the aggregate gross proceeds from any share sales. This fee structure directly ties their compensation to the dollar amount of stock Outlook Therapeutics actually sells under the program.
What happened to Outlook Therapeutics’ prior ATM program with BTIG?
Outlook Therapeutics terminated its prior at-the-market sales agreement with BTIG, which also allowed up to $100,000,000 in stock sales. Following this termination, the company will not offer or sell additional shares under the earlier BTIG-managed ATM program.
How much cash did Outlook Therapeutics report as of March 31, 2026?
The company reported preliminary, unaudited cash and cash equivalents of approximately $7.7 million as of March 31, 2026. This figure does not include $4.5 million of net proceeds from a registered direct equity offering completed in April 2026.
Is the March 31, 2026 cash balance for Outlook Therapeutics final and audited?
No. The approximately $7.7 million cash and cash equivalents figure is unaudited and preliminary. It is subject to normal quarterly closing processes and accounting review, so final results for the quarter may differ from this estimate.